Suppr超能文献

利用肝癌来源类器官评估过继性细胞转移的杀瘤效果。

Evaluation of the tumoricidal efficacy of adoptive cell transfer using hepatocellular carcinoma-derived organoids.

作者信息

Zhou Zizhen, Yan Xiaoluan, Shi Wanwan, Tan Kangan, Shao Chen, Wang Yan, Wang Guiqiang, Hong Yuan

机构信息

Infectious Diseases Department, Peking University First Hospital, Beijing, China.

General Surgery Department, Beijing Cancer Hospital, Beijing, China.

出版信息

J Gastrointest Oncol. 2022 Apr;13(2):732-743. doi: 10.21037/jgo-21-715.

Abstract

BACKGROUND

Tumor-derived organoid, namely tumoroid, can realistically retain the clinicopathologic features of original tumors even after long-term expansion. Here we develop this production methodology derived from hepatocellular carcinoma primary samples and generate a platform to evaluate the tumoricidal efficacy of autologous adoptive cell transfer including tumor infiltrating lymphocytes and peripheral blood lymphocytes.

METHODS

Haematoxylin and eosin together with immunohistochemistry staining were employed to ascertain the morphologic and histological features of tumoroids and original tumors. Tumor killing ability of T cells was detected by lactate dehydrogenase assay and propidium iodide staining. In tumoroid xenograft mouse model, tumor volumes were measured and T cell functions were examined by flow cytometry technique.

RESULTS

Four tumoroids with characteristics of poor differentiation and mild fibrosis were successfully established from fourteen hepatocellular carcinoma samples. More robust antitumor potential and hyper-functional phenotype of all four tumor infiltrating lymphocytes were observed compared to matched peripheral blood lymphocytes in coculture system. In tumoroid xenograft mouse models, however, only one patient-derived tumor infiltrating lymphocytes with the highest antitumor activity can bestow efficient tumor eradication.

CONCLUSIONS

Hepatocellular carcinoma tumoroid-based models could represent invaluable resources for evaluating the tumoricidal efficacy of autologous adoptive cell transfer. Tumor infiltrating lymphocytes should be a promising and yet-to-be-developed regimen to treat hepatocellular carcinoma.

摘要

背景

肿瘤来源的类器官,即肿瘤样组织,即使在长期扩增后也能真实保留原发肿瘤的临床病理特征。在此,我们开发了这种源自肝细胞癌原发样本的生产方法,并构建了一个平台来评估包括肿瘤浸润淋巴细胞和外周血淋巴细胞在内的自体过继性细胞转移的杀瘤效果。

方法

采用苏木精-伊红染色和免疫组织化学染色来确定肿瘤样组织和原发肿瘤的形态学和组织学特征。通过乳酸脱氢酶测定和碘化丙啶染色检测T细胞的肿瘤杀伤能力。在肿瘤样组织异种移植小鼠模型中,测量肿瘤体积,并通过流式细胞术技术检测T细胞功能。

结果

从14例肝细胞癌样本中成功建立了4个具有低分化和轻度纤维化特征的肿瘤样组织。在共培养系统中,与匹配的外周血淋巴细胞相比,观察到所有4种肿瘤浸润淋巴细胞具有更强的抗肿瘤潜力和超功能表型。然而,在肿瘤样组织异种移植小鼠模型中,只有1例具有最高抗肿瘤活性的患者来源的肿瘤浸润淋巴细胞能够有效根除肿瘤。

结论

基于肝细胞癌肿瘤样组织的模型可能是评估自体过继性细胞转移杀瘤效果的宝贵资源。肿瘤浸润淋巴细胞应该是一种有前景但尚未开发的治疗肝细胞癌的方案。

相似文献

2
Anti-tumor activity and mechanism of oligoclonal hepatocellular carcinoma tumor-infiltrating lymphocytes and .
Cancer Biol Ther. 2019;20(9):1187-1194. doi: 10.1080/15384047.2019.1599663. Epub 2019 Apr 24.
8
10
Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Clin Cancer Res. 2013 Nov 15;19(22):6151-62. doi: 10.1158/1078-0432.CCR-13-1189. Epub 2013 Sep 12.

引用本文的文献

1
State-of-the-Art Liver Cancer Organoids: Modeling Cancer Stem Cell Heterogeneity for Personalized Treatment.
BioDrugs. 2025 Mar;39(2):237-260. doi: 10.1007/s40259-024-00702-0. Epub 2025 Jan 18.
2
Precision models in hepatocellular carcinoma.
Nat Rev Gastroenterol Hepatol. 2025 Mar;22(3):191-205. doi: 10.1038/s41575-024-01024-w. Epub 2024 Dec 11.
3
Tumoroids, a valid preclinical screening platform for monitoring cancer angiogenesis.
Stem Cell Res Ther. 2024 Aug 26;15(1):267. doi: 10.1186/s13287-024-03880-4.
4
Toward reproducible tumor organoid culture: focusing on primary liver cancer.
Front Immunol. 2024 Mar 20;15:1290504. doi: 10.3389/fimmu.2024.1290504. eCollection 2024.

本文引用的文献

1
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial.
Nat Med. 2021 Aug;27(8):1410-1418. doi: 10.1038/s41591-021-01462-y. Epub 2021 Aug 12.
2
[Expert consensus on early screening strategies for liver cancer in China].
Zhonghua Gan Zang Bing Za Zhi. 2021 Jun 20;29(6):515-522. doi: 10.3760/cma.j.cn501113-20210605-00264.
3
Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors.
BMC Med. 2021 Jun 11;19(1):140. doi: 10.1186/s12916-021-02006-4.
5
Tumor-infiltrating lymphocytes in the immunotherapy era.
Cell Mol Immunol. 2021 Apr;18(4):842-859. doi: 10.1038/s41423-020-00565-9. Epub 2020 Nov 2.
6
Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma - Authors' replys.
Lancet Oncol. 2020 Sep;21(9):e413. doi: 10.1016/S1470-2045(20)30476-9.
7
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
8
[Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)].
Zhonghua Gan Zang Bing Za Zhi. 2020 Feb 20;28(2):112-128. doi: 10.3760/cma.j.issn.1007-3418.2020.02.004.
9
The promise of adoptive cellular immunotherapies in hepatocellular carcinoma.
Oncoimmunology. 2019 Oct 13;9(1):1673129. doi: 10.1080/2162402X.2019.1673129. eCollection 2020.
10
Epidemiology and surveillance for hepatocellular carcinoma: New trends.
J Hepatol. 2020 Feb;72(2):250-261. doi: 10.1016/j.jhep.2019.08.025.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验